Cargando…

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma

Despite the introduction of multiple new drugs and combination therapies, conventional dexamethasone remains a cornerstone in the treatment of multiple myeloma (MM). Its application is, however, limited by frequent adverse effects of which the increased infection rate may have the strongest clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metselaar, Josbert, Lammers, Twan, Boquoi, Amelie, Fenk, Roland, Testaquadra, Fabio, Schemionek, Mirle, Kiessling, Fabian, Isfort, Susanne, Wilop, Stefan, Crysandt, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981510/ https://www.ncbi.nlm.nih.gov/pubmed/36592287 http://dx.doi.org/10.1007/s13346-022-01268-6

Ejemplares similares

Challenges in nanomedicine clinical translation
por: Metselaar, Josbert M., et al.
Publicado: (2020)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
por: Kroon, Jan, et al.
Publicado: (2015)

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
por: Bütow, Marlena, et al.
Publicado: (2022)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
por: Boquoi, Amelie, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Recent Advances in Liposomal-Based Anti-Inflammatory Therapy
por: van Alem, Carla M. A., et al.
Publicado: (2021)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
por: Vieri, Margherita, et al.
Publicado: (2023)

Development and characterization of liposomal formulation of bortezomib
por: Deshantri, Anil K., et al.
Publicado: (2019)

Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment
por: Alaarg, Amr, et al.
Publicado: (2016)

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?
por: Zukovs, Romans, et al.
Publicado: (2022)

A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase
por: Besse, Helena C., et al.
Publicado: (2020)

Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma
por: Deshantri, Anil K., et al.
Publicado: (2020)

Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis
por: Wong, Chee Wai, et al.
Publicado: (2018)

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
por: Salimi, Azam, et al.
Publicado: (2022)

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
por: Boquoi, A., et al.
Publicado: (2022)

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study
por: Pelcovits, Ari, et al.
Publicado: (2023)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Nanomedicine formulations for combination therapies
por: Lammers, Twan, et al.
Publicado: (2010)

Dissociation between systemic and pulmonary anti‐inflammatory effects of dexamethasone in humans
por: Bartko, Johann, et al.
Publicado: (2016)

Biochemical and biophysical characterisation of immunoglobulin free light chains derived from an initially unbiased population of patients with light chain disease
por: Sternke-Hoffmann, Rebecca, et al.
Publicado: (2020)

PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease
por: Hu, Wei, et al.
Publicado: (2009)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Riboflavin-Targeted Drug Delivery
por: Darguzyte, Milita, et al.
Publicado: (2020)

Imaging-assisted anticancer nanotherapy
por: Dasgupta, Anshuman, et al.
Publicado: (2020)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance
por: Dadfar, Seyed Mohammadali, et al.
Publicado: (2020)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
por: Callander, Natalie, et al.
Publicado: (2014)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Clinical translation of gold nanoparticles
por: Zhang, Rui, et al.
Publicado: (2022)

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
por: Becker, P S, et al.
Publicado: (2016)

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
por: Ferreira-Silva, Margarida, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7r83ujcbc13jjj7etdnltb5mrm